Subject has received or plans to receive the following excluded therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy. Required Wash-out periods:
Subject has anticipated life expectancy >  months prior to leukapheresis and > months prior to lymphodepletion.
No prior anti-leukemic therapy except the following are allowed: <  week of corticosteroids, or hydroxyurea or emergent leukapheresis; longer steroid use for diseases other than leukemia is permitted
DONOR: Deemed unable to undergo marrow harvesting or PBSC mobilization and leukapheresis
Must be willing and able to accept at least three leukapheresis procedures
Use of any of the following:\r\n* Therapeutic doses of corticosteroids (defined as >  mg/day prednisone or equivalent) within  days prior to leukapheresis; physiologic replacement, topical, and inhaled steroids are permitted\r\n* Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) within  days of leukapheresis\r\n* Cytotoxic chemotherapeutic agents within  week of leukapheresis; oral chemotherapeutic agents are allowed if at least  half-lives have elapsed prior to leukapheresis\r\n* Low dose chemotherapy (e.g., bortezomib, lenalidomide, cyclophosphamide ?  mg/m^) given after leukapheresis to maintain disease control must be stopped ?  days prior to initiation of lymphodepleting chemotherapy\r\n* Lymphotoxic chemotherapeutic agents within  weeks of leukapheresis\r\n* Experimental agents within  weeks of leukapheresis unless progression is documented on therapy and at least  half-lives have elapsed prior to leukapheresis\r\n* Daratumumab or any other anti-CD monoclonal antibody therapy within  days of leukapheresis
Treatment with alemtuzumab within  months prior to leukapheresis, or treatment with clofarabine or cladribine within  months prior to leukapheresis
Use of any of the following:\r\n* Therapeutic doses of corticosteroids (defined as >  mg/day prednisone or equivalent) within  days prior to leukapheresis; physiologic replacement, topical, and inhaled steroids are permitted\r\n* Allogeneic hematopoietic stem cell transplant (allo-HSCT) within  days of leukapheresis\r\n* Cytotoxic chemotherapeutic agents within  week of leukapheresis; oral chemotherapeutic agents are allowed if at least  half-lives have elapsed prior to leukapheresis\r\n* Low dose chemotherapy (e.g., bortezomib, lenalidomide, cyclophosphamide =<  mg/m^) given after leukapheresis to maintain disease control must be stopped >=  days prior to initiation of lymphodepleting chemotherapy\r\n* Lymphotoxic chemotherapeutic agents within  weeks of leukapheresis\r\n* Experimental agents within  weeks of leukapheresis unless progression is documented on therapy and at least  half-lives have elapsed prior to leukapheresis
Must be willing and able to accept at least three leukapheresis procedures
Subject has anticipated life expectancy >  months prior to leukapheresis and > months prior to lymphodepletion.
CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION
Screening evaluation appropriate for leukapheresis and T-cell collection
CRITERIA FOR SCREENING: Any known contraindication to leukapheresis
CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION: Use of any of the following:\r\n* Cytotoxic or lymphotoxic agents (including prednisone >  mg/day or equivalent corticosteroid) within  week prior to leukapheresis; physiologic corticosteroid replacement, and topical or inhaled corticosteroids are not excluded\r\n* GVHD therapies within  weeks prior to leukapheresis (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti-IL-, or anti-IL-R)\r\n* Experimental agents within  weeks prior to leukapheresis unless progression is documented on therapy and at least  half-lives have elapsed prior to leukapheresis\r\n* Radiation within  weeks prior to leukapheresis unless there is progressive disease in irradiated lesions or there are additional non-irradiated, positron emission tomography (PET)-positive lesions \r\n* Allo-HSCT within  days prior to leukapheresis or donor lymphocyte infusion (DLI) within  weeks prior to leukapheresis\r\n* Treatment with cladribine within  months prior to leukapheresis\r\n* Treatment with alemtuzumab within  months prior to leukapheresis
Adequate vascular access for leukapheresis procedure
Treatment with alemtuzumab within  months of leukapheresis or fludarabine or cladribine within  months of leukapheresis
Experimental agents within  weeks of leukapheresis unless no response or disease progression is documented on the experimental therapy and at least  half-lives have elapsed prior to leukapheresis
Any condition contraindicating leukapheresis.
Must be willing and able to accept two leukapheresis procedures
Patients must be willing to provide at least  mL, and up to  mL, of whole blood obtained by phlebotomy and/or consent to leukapheresis for DC generation.
Known exclusion criteria for leukapheresis, JCAR, or durvalumab therapy
EXCLUSION CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION:
Screening evaluation appropriate for leukapheresis and T-cell collection
INCLUSION CRITERIA FOR TNBC: Patients must be off chemotherapy for a minimum of  weeks prior to planned leukapheresis
Must be willing and able to accept the leukapheresis procedure
Patients must be willing to undergo two leukapheresis procedures for the investigational component of this trial
Patient may be required to undergo leukapheresis (depending on the study phase/cohort) and must agree to leukapheresis if so assigned
DONOR: Capable of undergoing leukapheresis
Research participants' last dose of prior chemotherapy or radiation must be >=  weeks before leukapheresis; Note: this criterion is not applicable if the research participant's donor is undergoing leukapheresis
The last dose of prior chemotherapy, immunotherapy or radiation must be at least  weeks before the leukapheresis procedure
The last dose of investigational agents must be at least  weeks before leukapheresis procedure unless no response or disease progression is documented on the experimental therapy and at least  half-lives must have elapsed prior to leukapheresis
If research participant is undergoing leukapheresis, he/she must be at least  weeks from having received the last dose of immunosuppressant medications\r\n* Exceptions:\r\n** Steroids and tyrosine kinase inhibitors are allowed up to  days prior to leukapheresis\r\n** Research participant cannot be on more than  mg prednisone or equivalent doses of other corticosteroids at the time of leukapheresis
If research participant is undergoing leukapheresis the last dose of prior chemotherapy, immunotherapy or radiation must be at least  weeks before the leukapheresis procedure\r\n* Exception rule: the wash out period for Hydrea is  hours
ELIGIBILITY TO UNDERGO LYMPHODEPLETION:\r\n* Please note that none of these criteria are applicable of the research participant's donor is undergoing leukapheresis
Must be willing and able to accept at least two leukapheresis procedures
Patients must be willing to provide at least  mL, and up to  mL, of whole blood obtained by phlebotomy and/or consent to leukapheresis for DC generation.
Availability of production capacities for the patient's IMA product prior to the leukapheresis TREATMENT SCREENING:
Any condition contraindicating leukapheresis
DONOR: Able and willing to undergo leukapheresis
DONOR: Individuals deemed unable to undergo marrow harvesting or PBSC mobilization and leukapheresis
Subject who has had cytotoxic chemotherapy within  weeks prior to leukapheresis; immune therapy or biological therapy within  weeks prior to leukapheresis; corticosteroids or any other immunosuppressive therapy within  weeks prior to leukapheresis; tyrosine kinase inhibitor (TKI) (e.g. erlotinib, gefitinib) and any other anti-cancer treatment within  week prior to leukapheresis.
Investigational treatment within  weeks prior to leukapheresis; experimental anti-cancer vaccine within  months prior to leukapheresis in the absence of response or in the opinion of the Investigator is responding to an experimental vaccine given within  months prior to leukapheresis; any prior gene therapy using an integrating vector.
Unwilling to undergo two leukapheresis procedures; if patients are unable to undergo the leukapheresis procedures, then a -cc blood draw (green heparinized tubes) is permitted in place of the leukapheresis
Patients with medical conditions precluding leukapheresis
Must be willing and able to accept two leukapheresis procedures
Must be willing and able to accept at least two leukapheresis procedures
Emergency leukapheresis
Treatment with alemtuzumab within  months prior to leukapheresis, or treatment with clofarabine or cladribine within  months prior to leukapheresis
Emergency leukapheresis;
Use of any of the following medications or treatments within the noted time prior to leukapheresis:
Alemtuzumab within  months prior to leukapheresis
Cladribine within  months prior to leukapheresis
Fludarabine within  weeks prior to leukapheresis
Cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan within  weeks prior to leukapheresis
Venetoclax within  days prior to leukapheresis
Idelalisib within  days prior to leukapheresis
Lenalidomide within  day prior to leukapheresis
Experimental agents, including off-label use of approved drugs, within  weeks prior to leukapheresis unless progression is documented on the experimental therapy and at least  half-lives have elapsed prior to leukapheresis
Having received systemic immune suppressive therapy within  days prior to leukapheresis
Patients may receive hydroxyurea, steroids, or leukapheresis as necessary until day  of treatment
DONOR: Alternatively to a fresh unmodified leukapheresis product, previously collected cryopreserved peripheral blood stem cells (PBSC) after mobilization with G-CSF or cryopreserved unmodified leukapheresis product from the original donor can be used; if cryopreserved product is not available, the following criteria apply for the DLI product:
Steroids: Therapeutic doses of corticosteroids are prohibited within  days prior to leukapheresis.
Chemotherapies: Salvage chemotherapy must be stopped at least  week prior to leukapheresis
Treatment with alemtuzumab within  months prior to leukapheresis, or treatment with clofarabine or cladribine within  months prior to leukapheresis
Donor must be able to undergo leukapheresis
DONOR: Able and willing to undergo leukapheresis
CRITERIA FOR LEUKAPHERESIS:
Known infection with hepatitis B virus (HBV) and hepatitis C virus (HCV); (if a patient was not tested at the time of their leukapheresis, they must be tested prior to receiving T cell infusion; if testing was done for leukapheresis, this is adequate and does not need to be repeated)
Patients may receive hydroxyurea, steroids, or leukapheresis as necessary until day  of treatment
Leukapheresis;
Treatment with alemtuzumab within  months of leukapheresis, or treatment with fludarabine or cladribine within  months of leukapheresis
Experimental agents within  weeks of leukapheresis unless no response or disease progression is documented on the experimental therapy and at least  half-lives have elapsed prior to leukapheresis.
GVHD therapies within  weeks of leukapheresis and JCAR administration.
Radiation within  weeks of leukapheresis.
Inability to undergo leukapheresis
Patients may receive anagrelide for up to  days (in countries where the product is registered). Leukapheresis is allowed up to  hours prior to the first treatment cycle with omacetaxine.
Leukapheresis ?  weeks prior to starting CC-.